Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
NCT04557306
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
BIOLOGICAL:
CBT101 cells, every 2 weeks
BIOLOGICAL:
CBT101 cells, every 4 weeks
Sponsor
CHABiotech CO., Ltd